Curasight A/S

Curasight operates in the pharmaceutical industry. The company specializes in the development of technological products. The product portfolio has its main focus in the development of innovative technologies for the diagnosis and treatment of cancer based on targeted PET imaging and radionuclide therapy. The business is operated with the largest presence in Scandinavia. Curasight is headquartered in Copenhagen.

Quotes for Curasight A/S

Board

CEO

  • Ulrich Krasilnikoff

Chairperson of the Board

  • Kirsten Drejer

Board

  • Andreas Kjær
  • Colin Hayward
  • Marcel Reichen
  • Ulrich Krasilnikoff

Videos

1 / 1
CompanyPresentation Curasight - Providing answers for cancer patients
Powered by Modular Finance
*Powered by Modular Finance
Key Numbers
2026-03-31 2025-12-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Number of months that the report spans Q1 3 Months 2025 Q4 3 Months Q3 3 Months Q2 3 Months Q1 3 Months 2024
Total revenue MDKK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings before interest and tax MDKK -15.28 -55.59 -16.82 -13.55 -19.01 -6.21 -40.37
Profit before tax MDKK -16.70 -58.73 -17.31 -14.26 -20.58 -6.58 -42.34
Net profit MDKK -15.33 -53.23 -15.94 -12.89 -19.20 -5.20 -38.21
Earnings per share DKK -0.32 -1.10 -0.14 -0.28 -0.43 -0.25 -1.81
Dividend per share DKK 0,00 0.00 0.00 0,00 0,00 0,00 0.00
Equity MDKK 6.89 17.94 17.94 17.47 30.30 2.51 6.34
Fixed assets MDKK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible assets MDKK 5.81 6.01 6.01 6.22 6.42 6.62 6.83
Current assets MDKK 30.36 43.97 43.97 26.93 38.31 10.99 15.44
Total asset MDKK 36.25 50.06 50.06 33.20 44.78 17.66 22.31
Long term liabilities MDKK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current liabilities MDKK 29.35 32.12 32.12 15.73 14.48 15.15 15.98
Number of shares DKK 48352204.00 47922841.00 47922841.00 45867511.00 44886242.00 21148880.00 21148880.00
*Compiled data from Millistream